Norges Bank
BBIO icon

Norges Bank’s BridgeBio Pharma BBIO Stock Holding History

Norges Bank’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,527,028
Closed -$117M – 158
2025
Q4 		$117M Buy
+1,527,028
New +$100M 0.01% 696
2025
Q3 		– Sell
-1,956,654
Closed -$84.5M – 179
2025
Q2 		$84.5M Buy
1,956,654
+711,699
+57% +$25.9M 0.01% 766
2025
Q1 		$43M Buy
1,244,955
+179,476
+17% +$6.05M 0.01% 998
2024
Q4 		$29.2M Sell
1,065,479
-77,953
-7% -$2.01M ﹤0.01% 1154
2024
Q3 		$29.1M Buy
1,143,432
+249,703
+28% +$6.56M ﹤0.01% 1153
2024
Q2 		$22.6M Sell
893,729
-189,994
-18% -$5.19M ﹤0.01% 1188
2024
Q1 		$33.5M Sell
1,083,723
-76,619
-7% -$2.61M 0.01% 1105
2023
Q4 		$46.8M Buy
1,160,342
+664,254
+134% +$19.9M 0.01% 934
2023
Q3 		$13.1M Sell
496,088
-266,218
-35% -$7.55M ﹤0.01% 1374
2023
Q2 		$13.1M Hold
762,306
– – ﹤0.01% 1431
2023
Q1 		$12.6M Sell
762,306
-198,289
-21% -$2.31M ﹤0.01% 1486
2022
Q4 		$7.32M Hold
960,595
– – ﹤0.01% 1662
2022
Q3 		$9.55M Hold
960,595
– – ﹤0.01% 1557
2022
Q2 		$8.72M Sell
960,595
-133,300
-12% -$1.11M ﹤0.01% 1614
2022
Q1 		$11.1M Buy
1,093,895
+192,400
+21% +$1.97M ﹤0.01% 1670
2021
Q4 		$15M Buy
901,495
+68,263
+8% +$2.89M ﹤0.01% 1604
2021
Q3 		$39.1M Buy
833,232
+8,800
+1% +$472K 0.01% 1053
2021
Q2 		$50.3M Buy
824,432
+95,603
+13% +$5.46M 0.01% 962
2021
Q1 		$44.9M Buy
728,829
+95,845
+15% +$6.27M 0.01% 1037
2020
Q4 		$45M Buy
632,984
+59,921
+10% +$2.89M 0.01% 1047
2020
Q3 		$21.5M Buy
573,063
+451,246
+370% +$14.2M 0.01% 1379
2020
Q2 		$3.97M Hold
121,817
– – ﹤0.01% 1891
2020
Q1 		$3.53M Hold
121,817
– – ﹤0.01% 1871
2019
Q4 		$4.27M Sell
121,817
-28,183
-19% -$781K ﹤0.01% 1923
2019
Q3 		$3.22M Sell
150,000
-150,000
-50% -$4.15M ﹤0.01% 1956
2019
Q2 		$8.09M Buy
+300,000
New +$8.18M ﹤0.01% 1859

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's BBIO Position: Q1 2026 in Review

Norges Bank sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 1,527,028 shares — an estimated $117M sold.

Norges Bank first reported a position in BBIO in Q2 2019 and held it in 26 quarters. The position peaked at $117M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Norges Bank reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Norges Bank sold 1,527,028 BridgeBio Pharma shares in Q1 2026, an estimated $117M.
  • Norges Bank first reported a position in BridgeBio Pharma in Q2 2019 and held it in 26 quarters.
  • Norges Bank's BridgeBio Pharma position peaked at $117M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.